Bleb injections ward off orbital tumours

Article

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Professor Brian Mohney and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, completed a non-comparative interventional case series on two patients who presented with bilateral retinoblastoma.

Subconjunctival chemotherapy was administered to both patients to reduce the risk or orbital tumour seeding after intravitreal injection. The outcome measures were ocular toxicity levels and the presence or absence of viable tumour cells at the injection site.

Subconjunctival chemotherapy bleb injections before intravitreal drug delivery seem to reduce the risk of orbital tumour seeding in patients with advanced stage retinoblastoma.

The paper was recently published in the British Journal of Ophthalmology and is available by clicking here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
© 2024 MJH Life Sciences

All rights reserved.